Get startedLog in
    Picture of Newbury Pharmaceuticals AB logo

    NEWBRY — Newbury Pharmaceuticals AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    Consumer DefensivesHighly SpeculativeMicro CapMomentum Trap
    All News

    Brief: Newbury Q3 EBITDA Loss Widens To SEK 3.1 Mln

    Picture of Newbury Pharmaceuticals AB logoNewbury Pharmaceuticals AB
    06/07/2022 07:08
    July 6 (Reuters) - Newbury Pharmaceuticals AB  NEWBRY.ST :
    * NEWBURY PHARMACEUTICALS INTERIM REPORT SEPTEMBER 2021 –
MAY 2022
    * Q3 NET REVENUE WAS 644 (732) TKR.
    * Q3 EBITDA WAS -3 100 (-2 079) TKR.

Source text for Eikon:  ID:nMFN1j8k1G 
Further company coverage:  NEWBRY.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

    Recent news on Newbury Pharmaceuticals AB

    See all news